Objective:To investigate the occurrence of malignancy in psoriatic arthritis (PsA) patients, and further explore the factors related to malignancy.Methods:Based on the PsA prospective follow-up cohort (PKUPsA-PC) in our center, we collected the demographics and clinical characteristics of patients who visited from January 2016 to January 2024, especially those regarding the malignant tumor. The clinical characteristics of patients with and without malignant tumor were compared through the method of non-parametric tests and chi-square tests. Multivariate logistic regression was applied to analyze the factors related to malignant tumors.Results:Three hundred and eighty two patients with PsA were enrolled. The median follow-up duration was 6.0 (2.8,12.8) years. Twenty two (5.8%) patients were complicated with malignant tumors. The median age of confirmed tumors was 56.4 (45.8, 67.3) years. Among them, 14 (63.6%) patients were female, and 16 (72.7%) patients had malignant tumors after the diagnosis of PsA. As for the tumor types, solid tumors were great majority (21 cases, 95.5%), including breast cancer (7 cases), urinary system tumors (5 cases), skin cancer (3 cases), colorectal/rectal cancer (2 cases), and thyroid cancer, liver cancer, endometrial carcinoma in situ, retroperitoneal malignant tumor (1 case respectively). There was only 1 (4.5%) patient with hematological tumor (chronic lymphocytic leukemia). Compared with patients without malignant tumors, PsA patients with malignancy had a higher proportion of women (63.6% vs. 40.8%, χ2=4.42, P=0.035), older age [56.4 (45.8, 67.3)years vs. 47.0 (36.0, 56.6) years, Z=-2.94, P=0.003], had a longer duration of psoriasis [20.0 (11.2, 33.5)years vs. 14.0 (6.0, 23.0) years, Z=-2.02, P=0.043], a longer duration of arthritis [8.0 (4.0, 17.0)years vs. 3.0 (1.0, 7.0) years, Z=-2.65, P=0.008], and a higher proportion of HLA-B27 positivity (25.0% vs. 4.4%, χ2=3.98, P=0.046). Age[ OR(95% CI)=1.056(1.008, 1.107), P=0.023], duration of PsA [ OR(95% CI)=1.051( 1.068, 1.106), P=0.010], and HLA-B27 positivity [ OR(95% CI)=5.086(1.278, 20.238), P=0.021] were the factors related to the occurrence of malignancy in PsA patients. Conclusion:Malignancy is not rare in PsA patients. Breast cancer, urinary system tumors and skin cancer are relatively common. PsA patients with older age, longer duration of PsA and positive HLA-B27 are more likely to have malignancy, which arouses more alert.

Objective:To explore the distribution variation of ultrasound-detected inflammatory lesions with clinical signs in patients with psoriatic arthritis (PsA).Methods:This was based on the Peking University First Hospital Psoriatic Arthritis (PKUPsA) cohort. Patients enrolled from January 2019 to June 2024 were inchuded, patients with complete data of physical examination and ultrasonographic evaluations of 62 joints in the hand and foot. The ultrasound-detected inflammatory lesions including synovitis, tenosynovitis, enthesitis, and soft tissue inflammation were compared with joint tenderness/swelling. The χ2 test was employed to analyze differences between groups. Results:A total of 7 440 joints in 120 PsA patients were included. Overall, the proportion of joints with clinical signs (tenderness or swelling) was higher than those with ultrasound-detected inflammatory lesions [9.14%(680/7 440) vs. 7.93%(590/7 440), χ2=1 245.928, P<0.001], with more tenderness joints than swelling joints [7.72%(574/7 440) vs. 6.14%(457/7 440), χ2=3 264.45, P<0.001]. Clinical signs were primarily observed in hand proximal interphalangeal (PIP), distal interphalangeal (DIP), wrist and ankle joints, mostly in DIP2 joints [19.58%(47/240)]. Ultrasound-detected inflammatory lesions were predominantly found in metatarsophalangeal (MTP), wrist, and ankle joints, mostly in MTP2 joints (18.75%, 45/240). Clinical signs were more prevalent than ultrasound-detected inflammatory lesions in hand PIP1-3, PIP5, DIP2, and DIP5 joints ( P<0.05), whereas more frequent ultrasound-detected inflammatory lesions than clinical tenderness/swelling were in MTP1-4 joints ( P<0.05). Among ultrasound-detected inflammatory lesions, synovitis in MTP2 joints (18.75%, 45/240), tenosynovitis in ankle joints (10.00%, 24/240), enthesitis in hand DIP2 joints (8.75%, 21/240), and soft tissue inflammation in MTP4 joints (2.50%, 6/240) most commonly observed. Dactylitis was more frequently observed in toes than in fingers, with the fourth toe most commonly affected(16.67%, 40/240). Ultrasound-detected inflammatory lesions were observed in 72.37%(55/240) of fingers/toes with clinical dactylitis, mainly presenting as synovitis, tenosynovitis, or combinations of these. Conclusion:PsA exhibits significant heterogeneity in the inflammatory lesions across different joints and lesion types. The discrepancies between clinical findings and ultrasonic inflammatory changes highlight the limitations of physical examination in fully capturing the pathological features of PsA. As a critical tool for PsA evaluation, ultrasonography offers distinct advantages in detecting subclinical inflammation and differentiating inflammatory from non-inflammatory lesions.

Objective:To investigate the occurrence of malignancy in psoriatic arthritis (PsA) patients, and further explore the factors related to malignancy.Methods:Based on the PsA prospective follow-up cohort (PKUPsA-PC) in our center, we collected the demographics and clinical characteristics of patients who visited from January 2016 to January 2024, especially those regarding the malignant tumor. The clinical characteristics of patients with and without malignant tumor were compared through the method of non-parametric tests and chi-square tests. Multivariate logistic regression was applied to analyze the factors related to malignant tumors.Results:Three hundred and eighty two patients with PsA were enrolled. The median follow-up duration was 6.0 (2.8,12.8) years. Twenty two (5.8%) patients were complicated with malignant tumors. The median age of confirmed tumors was 56.4 (45.8, 67.3) years. Among them, 14 (63.6%) patients were female, and 16 (72.7%) patients had malignant tumors after the diagnosis of PsA. As for the tumor types, solid tumors were great majority (21 cases, 95.5%), including breast cancer (7 cases), urinary system tumors (5 cases), skin cancer (3 cases), colorectal/rectal cancer (2 cases), and thyroid cancer, liver cancer, endometrial carcinoma in situ, retroperitoneal malignant tumor (1 case respectively). There was only 1 (4.5%) patient with hematological tumor (chronic lymphocytic leukemia). Compared with patients without malignant tumors, PsA patients with malignancy had a higher proportion of women (63.6% vs. 40.8%, χ2=4.42, P=0.035), older age [56.4 (45.8, 67.3)years vs. 47.0 (36.0, 56.6) years, Z=-2.94, P=0.003], had a longer duration of psoriasis [20.0 (11.2, 33.5)years vs. 14.0 (6.0, 23.0) years, Z=-2.02, P=0.043], a longer duration of arthritis [8.0 (4.0, 17.0)years vs. 3.0 (1.0, 7.0) years, Z=-2.65, P=0.008], and a higher proportion of HLA-B27 positivity (25.0% vs. 4.4%, χ2=3.98, P=0.046). Age[ OR(95% CI)=1.056(1.008, 1.107), P=0.023], duration of PsA [ OR(95% CI)=1.051( 1.068, 1.106), P=0.010], and HLA-B27 positivity [ OR(95% CI)=5.086(1.278, 20.238), P=0.021] were the factors related to the occurrence of malignancy in PsA patients. Conclusion:Malignancy is not rare in PsA patients. Breast cancer, urinary system tumors and skin cancer are relatively common. PsA patients with older age, longer duration of PsA and positive HLA-B27 are more likely to have malignancy, which arouses more alert.

Objective:To explore the distribution variation of ultrasound-detected inflammatory lesions with clinical signs in patients with psoriatic arthritis (PsA).Methods:This was based on the Peking University First Hospital Psoriatic Arthritis (PKUPsA) cohort. Patients enrolled from January 2019 to June 2024 were inchuded, patients with complete data of physical examination and ultrasonographic evaluations of 62 joints in the hand and foot. The ultrasound-detected inflammatory lesions including synovitis, tenosynovitis, enthesitis, and soft tissue inflammation were compared with joint tenderness/swelling. The χ2 test was employed to analyze differences between groups. Results:A total of 7 440 joints in 120 PsA patients were included. Overall, the proportion of joints with clinical signs (tenderness or swelling) was higher than those with ultrasound-detected inflammatory lesions [9.14%(680/7 440) vs. 7.93%(590/7 440), χ2=1 245.928, P<0.001], with more tenderness joints than swelling joints [7.72%(574/7 440) vs. 6.14%(457/7 440), χ2=3 264.45, P<0.001]. Clinical signs were primarily observed in hand proximal interphalangeal (PIP), distal interphalangeal (DIP), wrist and ankle joints, mostly in DIP2 joints [19.58%(47/240)]. Ultrasound-detected inflammatory lesions were predominantly found in metatarsophalangeal (MTP), wrist, and ankle joints, mostly in MTP2 joints (18.75%, 45/240). Clinical signs were more prevalent than ultrasound-detected inflammatory lesions in hand PIP1-3, PIP5, DIP2, and DIP5 joints ( P<0.05), whereas more frequent ultrasound-detected inflammatory lesions than clinical tenderness/swelling were in MTP1-4 joints ( P<0.05). Among ultrasound-detected inflammatory lesions, synovitis in MTP2 joints (18.75%, 45/240), tenosynovitis in ankle joints (10.00%, 24/240), enthesitis in hand DIP2 joints (8.75%, 21/240), and soft tissue inflammation in MTP4 joints (2.50%, 6/240) most commonly observed. Dactylitis was more frequently observed in toes than in fingers, with the fourth toe most commonly affected(16.67%, 40/240). Ultrasound-detected inflammatory lesions were observed in 72.37%(55/240) of fingers/toes with clinical dactylitis, mainly presenting as synovitis, tenosynovitis, or combinations of these. Conclusion:PsA exhibits significant heterogeneity in the inflammatory lesions across different joints and lesion types. The discrepancies between clinical findings and ultrasonic inflammatory changes highlight the limitations of physical examination in fully capturing the pathological features of PsA. As a critical tool for PsA evaluation, ultrasonography offers distinct advantages in detecting subclinical inflammation and differentiating inflammatory from non-inflammatory lesions.

BACKGROUND: Vaccination has been shown effective in controlling the global coronavirus disease 2019 (COVID-19) pandemic and reducing severe cases. This study was to assess the flare and change in disease activity after COVID-19 vaccination in patients with stable rheumatoid arthritis (RA). METHODS: A prospective cohort of RA patients in remission or with low disease activity was divided into a vaccination group and a non-vaccination group based on their COVID-19 vaccination status. Each of them was examined every 3 to 6 months. In the vaccination group, disease activity was compared before and after vaccination. The rates of flare defined as disease activity scores based on 28-joint count (DAS28) >3.2 with ΔDAS28 ≥0.6 were compared between vaccination and non-vaccination groups. RESULTS: A total of 202 eligible RA patients were enrolled. Of these, 98 patients received no vaccine shot (non-vaccination group), and 104 patients received two doses of vaccine (vaccination group). The median time interval from pre-vaccination visit to the first immunization and from the second dose of vaccine to post-vaccination visit was 67 days and 83 days, respectively. The disease activity scores at pre-vaccination and post-vaccination visits in the vaccination group patients were similar. At enrollment, gender, RA disease course, seropositivity, and disease activity were comparable across the two groups. Flare was observed in five (4.8%) of the vaccination group patients and nine (9.2%) of the non-vaccination group patients at post-vaccination assessment ( P  = 0.221). In terms of safety, 29 (27.9%) patients experienced adverse events (AEs) after vaccination. No serious AEs occurred. CONCLUSIONS COVID-19 vaccinations had no significant effect on disease activity or risk of flare in RA patients in remission or with low disease activity. Patients with stable RA should be encouraged to receive the COVID-19 vaccination.
Humans ; Arthritis, Rheumatoid ; Cohort Studies ; COVID-19/prevention & control* ; COVID-19 Vaccines/adverse effects* ; East Asian People ; Prospective Studies ; Vaccination/adverse effects*

Rheumatoid arthritis (RA) is an autoimmune disease characterized by synovial inflammation of the joints with high risk of disability. In recent years, remarkable progress has been made towards the diagnosis and treatment of RA, and the international RA guidelines have been also kept updated. Nevertheless, there are many challenges in China, especially inadequate number of rheumatologists and insufficient experience in the diagnosis and treatment of RA. Therefore, Chinese Rheumatology Association drafted the standardized diagnosis and treatment of RA based on the available evidence, so as to improve the management of RA patients in China.

Febuxostat, a new selective xanthine oxidase inhibitor, is approved by the U.S. Food and Drug Administration in 2009 for the treatment of gout and hyperuricemia. The study on the "cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities (CARES)", which was published in 2018, showed that febuxostat could increase the risk of all-cause mortality and cardiovascular related death in gout patients with cardiovascular disease. However, the subsequent clinical studies have not confirmed that febuxostat could increase the risk of cardiovascular events-related death. The inconsistent results of the studies on cardiovascular safety of febuxostat suggest that the gout patients with cardiovascular disease may benefit from continuous uric acid lowering therapy. However, during the process of using febuxostat, the risk of cardiovascular events and cardiovascular events-related death should be alerted, the combination medication and renal function of patients should be paid attention to, and the xanthine oxidase inhibitor withdrawal syndrome should be prevented.

Febuxostat, a new selective xanthine oxidase inhibitor, is approved by the U.S. Food and Drug Administration in 2009 for the treatment of gout and hyperuricemia. The study on the "cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities (CARES)", which was published in 2018, showed that febuxostat could increase the risk of all-cause mortality and cardiovascular related death in gout patients with cardiovascular disease. However, the subsequent clinical studies have not confirmed that febuxostat could increase the risk of cardiovascular events-related death. The inconsistent results of the studies on cardiovascular safety of febuxostat suggest that the gout patients with cardiovascular disease may benefit from continuous uric acid lowering therapy. However, during the process of using febuxostat, the risk of cardiovascular events and cardiovascular events-related death should be alerted, the combination medication and renal function of patients should be paid attention to, and the xanthine oxidase inhibitor withdrawal syndrome should be prevented.

By removing a part of the structure, the tooth preparation provides restorative space, bonding surface, and finish line for various restorations on abutment. Preparation technique plays critical role in achieving the optimal result of tooth preparation. With successful application of microscope in endodontics for >30 years, there is a full expectation of microscopic dentistry. However, as relatively little progress has been made in the application of microscopic dentistry in prosthodontics, the following assumptions have been proposed: Is it suitable to choose the tooth preparation technique under the naked eye in the microscopic vision? Is there a more accurate preparation technology intended for the microscope? To obtain long-term stable therapeutic effects, is it much easier to achieve maximum tooth preservation and retinal protection and maintain periodontal tissue and oral function health under microscopic vision? Whether the microscopic prosthodontics is a gimmick or a breakthrough in obtaining an ideal tooth preparation should be resolved in microscopic tooth preparation. This article attempts to illustrate the concept, core elements, and indications of microscopic minimally invasive tooth preparation, physiological basis of dental pulp, periodontium and functions involved in tool preparation, position ergonomics and visual basis for dentists, comparison of tooth preparation by naked eyes and a microscope, and comparison of different designs of microscopic minimally invasive tooth preparation techniques. Furthermore, a clinical protocol for microscopic minimally invasive tooth preparation based on target restorative space guide plate has been put forward and new insights on the quantity and shape of microscopic minimally invasive tooth preparation has been provided.

Objective To explore the risk factors of urate deposition on ultrasound in patients with gout.Methods All the gout patients who visited our center between February 2015 and February 2017 and underwent ultrasound examination of bilateral knees,ankles and first metatarsophalangeal joints (MTP1) were enrolled.Subgroup analysis was done depending on whether double contour sign (DCS) or tophus was found on ultrasound.Main statistical analysis methods were t test,chi-square test and logistic regression model.Results One hundred and twenty-six patients were included.DCS was found in 50(39.7％) patients and tophus was found in 48 (38.1％) patients.The serum uric acid (SU) level of the DCS positive group was signi-ficantly higher than the DCS negative group [(602±79) μmol/L vs (538±101) μmol/L,t=3.998,P=0.044].The hyperuicemia duration of the two groups were (186±87) months and (130±77) months,which was significantly different (t=3.330,P=0.002).The hyperuicemia duration of the tophus positive group was significantly higher than tophus negative group [(175±102) months vs (138±96) months,t=2.003,P=0.045].The SU level and hyperuicemia duration were independent risk factors of positive DCS in gout patients [OR =1.006,95％ CI (1.002,1.01 1);OR=1.028,95％CI (1.013,1.042)].The hyperuicemia duration was independent risk factor of positive tophus in gout patients [OR=1.004,95％CI (1.000,1.007)].Receiver operating characteristic curve (ROC) curve showed gout patient whose hyperuricemia duration was longer than 94months and SU level was higher than 505.5 μmol/L were more likely to have positive DCS in joints;meanwhile,patient whose hyperuricemia duration was longer than 137 months were more likely to have positive tophus in joints.Conclusion Gout patients who have positive DCS and tophus on ultrasound have longer hyperuicemia duration.Positive DCS is also related with patients' higher serum levels.The hyperuicemia duration is an independent risk factor of urate deposition on ultrasound in patients with gout.